Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
about
High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to PaclitaxelBetter pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialNeoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis.
P2860
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Pathologic complete response r ...... l with or without trastuzumab.
@ast
Pathologic complete response r ...... l with or without trastuzumab.
@en
type
label
Pathologic complete response r ...... l with or without trastuzumab.
@ast
Pathologic complete response r ...... l with or without trastuzumab.
@en
prefLabel
Pathologic complete response r ...... l with or without trastuzumab.
@ast
Pathologic complete response r ...... l with or without trastuzumab.
@en
P2093
P2860
P1433
P1476
Pathologic complete response r ...... l with or without trastuzumab.
@en
P2093
Arvind M Shinde
Courtney Vito
George Somlo
John H Yim
Kim Wai Yu
Laura Kruper
Michele Kirschenbaum
Nayana L Vora
Paul Frankel
P2860
P356
10.1016/J.BREAST.2014.10.008
P577
2014-11-20T00:00:00Z